SFM
PBAXU

Spartan Fund Management’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Spartan Fund Management’s Portfolio PBAXU Stock Details PBAXU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,000
Closed -$503K – 474
2022
Q2 		$503K Hold
50,000
– – 0.11% 260
2022
Q1 		$629K Buy
+50,000
New +$505K 0.1% 268

Other funds holding PBAXU

SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $46.4M AUM 13.94% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

Spartan Fund Management's PBAXU Position: Q3 2022 in Review

Spartan Fund Management sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q3 2022, closing a stake of 50,000 shares — an estimated $503K sold.

Spartan Fund Management first reported a position in PBAXU in Q1 2022 and held it in 2 quarters. The position peaked at $629K in Q1 2022. 21 funds tracked by Wall St. Rank hold PBAXU as of Q3 2022.

  • Spartan Fund Management reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q3 2022 after selling out during the quarter.
  • Spartan Fund Management sold 50,000 Phoenix Biotech Acquisition Corp. Unit shares in Q3 2022, an estimated $503K.
  • Spartan Fund Management first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q1 2022 and held it in 2 quarters.
  • Spartan Fund Management's Phoenix Biotech Acquisition Corp. Unit position peaked at $629K in Q1 2022.
  • 21 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q3 2022.

Based on Spartan Fund Management's 13F filing for Q3 2022, filed 26 Oct 2022.